uniQure (QURE) Expected to Announce Quarterly Earnings on Thursday

uniQure (NASDAQ:QURE) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect uniQure to post earnings of ($0.93) per share and revenue of $4.8350 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 2, 2026 at 8:00 AM ET.

uniQure Stock Performance

Shares of QURE stock opened at $24.47 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -5.57 and a beta of 0.66. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50. The firm’s 50-day simple moving average is $23.68 and its two-hundred day simple moving average is $29.62.

Insiders Place Their Bets

In other news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director directly owned 20,439 shares in the company, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently bought and sold shares of QURE. Virtus Investment Advisers LLC increased its holdings in uniQure by 91.6% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 6,520 shares during the period. SummitTX Capital L.P. grew its position in shares of uniQure by 386.3% during the 4th quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock valued at $663,000 after purchasing an additional 22,010 shares in the last quarter. Suvretta Capital Management LLC bought a new position in shares of uniQure in the fourth quarter worth $29,116,000. Readystate Asset Management LP bought a new position in shares of uniQure in the fourth quarter worth $8,652,000. Finally, Orbimed Advisors LLC raised its position in shares of uniQure by 60.8% in the fourth quarter. Orbimed Advisors LLC now owns 737,400 shares of the biotechnology company’s stock worth $17,646,000 after buying an additional 278,900 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Upcoming catalyst — uniQure will report fourth-quarter and full‑year 2025 results before the market opens on March 2, 2026, followed by an 8:00 a.m. ET conference call. Results and management commentary could clarify revenue, commercialization progress for its hemophilia B gene therapy and development timelines for Huntington’s, ALS and other programs — a potential positive catalyst if results or guidance beat expectations. uniQure to Announce 2025 Financial Results
• Neutral Sentiment: Mixed market signals — a QuiverQuant summary highlights strong analyst interest (multiple buy/outperform ratings and a median 6‑month target around $53) but also notes heavy insider selling over the past 6 months and shifting institutional positions. Analysts’ optimism is a tailwind, but insider sales and recent portfolio churn create mixed signals for near‑term sentiment. uniQure N.V. to Report Q4 and Full Year 2025 Financial Results on March 2, 2026
• Negative Sentiment: Legal overhang — multiple plaintiff firms have filed or solicited investors for a securities‑class action covering purchases between Sept. 24 and Oct. 31, 2025, and are urging investors to contact counsel; firms include Rosen, Levi & Korsinsky, Berger Montague, Schall and DJS. They cite alleged securities‑law violations and set an April 13, 2026 lead‑plaintiff deadline. The proliferation of suits increases litigation risk, potential legal expenses and an investor overhang that can weigh on the share price until resolved. ROSEN Encourages uniQure Investors to Secure Counsel Levi & Korsinsky Class Action Notice Berger Montague Investor Alert

Analysts Set New Price Targets

A number of equities research analysts recently commented on QURE shares. Benchmark reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. William Blair reissued a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Cantor Fitzgerald restated an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. The Goldman Sachs Group dropped their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Finally, Chardan Capital reissued a “buy” rating and issued a $53.00 price objective on shares of uniQure in a report on Thursday, December 4th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $58.33.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.